# A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

> **NCT06024239** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers
- Generalized Anxiety Disorder (GAD)
- Bipolar Disorder (BPD)

## Interventions

- **DRUG:** ABBV-932
- **DRUG:** Placebo for ABBV-932

## Key facts

- **NCT ID:** NCT06024239
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-31
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-03-04
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024239, "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06024239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*